Avenue Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Avenue Therapeutics has a total shareholder equity of $3.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.0M and $1.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.92m |
| Equity | US$3.83m |
| Total liabilities | US$1.16m |
| Total assets | US$4.99m |
Recent financial health updates
We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate
Mar 19
We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate
Dec 19Recent updates
Avenue Therapeutics shares slide on pricing $12M securities offering
Oct 07Avenue Therapeutics up 4% on 1-for-15 reverse stock split
Sep 22Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine
Jun 14We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate
Mar 19How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?
Jan 23We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate
Dec 19Avenue Therapeutics issues regulatory update for IV tramadol
Dec 17Financial Position Analysis
Short Term Liabilities: ATXI's short term assets ($5.0M) exceed its short term liabilities ($1.2M).
Long Term Liabilities: ATXI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ATXI is debt free.
Reducing Debt: ATXI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATXI has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ATXI has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.1% each year.